|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harris TJ and McCormick F: The molecular
pathology of cancer. Nat Rev Clin Oncol. 7:251–265. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mármol I, Sánchez-de-Diego C, Pradilla
Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A
general overview and future perspectives in colorectal cancer. Int
J Mol Sci. 18:1972017. View Article : Google Scholar
|
|
6
|
Goryca K, Kulecka M, Paziewska A,
Dabrowska M, Grzelak M, Skrzypczak M, Ginalski K, Mroz A, Rutkowski
A, Paczkowska K, et al: Exome scale map of genetic alterations
promoting metastasis in colorectal cancer. BMC Genet. 19:852018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valeri N, Gasparini P, Fabbri M, Braconi
C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, et
al: Modulation of mismatch repair and genomic stability by miR-155.
Proc Natl Acad Sci USA. 107:6982–6987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van den Berg A, Mols J and Han J:
RISC-target interaction: Cleavage and translational suppression.
Biochim Biophys Acta. 1779:668–677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong YG, Xin C, Zheng H, Huang ZP, Yang Y,
Zhou JD, Gao XH, Hao L, Liu QZ, Zhang W and Hao LQ: miR-365a-3p
regulates ADAM10-JAK-STAT signaling to suppress the growth and
metastasis of colorectal cancer cells. J Cancer. 11:3634–3644.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Wang Z, Chen M, Peng L, Wang X,
Ma Q, Ma F and Jiang B: MicroRNA-143 targets MACC1 to inhibit cell
invasion and migration in colorectal cancer. Mol Cancer. 11:232012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Cao F, Li X, Miao H, E J, Xing J
and Fu CG: miR-320b suppresses cell proliferation by targeting
c-Myc in human colorectal cancer cells. BMC Cancer. 15:7482015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li YC, Li CF, Chen LB, Li DD, Yang L, Jin
JP and Zhang B: MicroRNA-766 targeting regulation of SOX6
expression promoted cell proliferation of human colorectal cancer.
Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Wang X, Wen C, Yang X, Song M,
Chen J, Wang C, Zhang B, Wang L, Iwamoto A, et al: Hsa-miR-19a is
associated with lymph metastasis and mediates the TNF-α induced
epithelial-to-mesenchymal transition in colorectal cancer. Sci Rep.
5:133502015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Zhou Y, Feng X, An P, Quan X, Wang
H, Ye S, Yu C, He Y and Luo H: MicroRNA-126 functions as a tumor
suppressor in colorectal cancer cells by targeting CXCR4 via the
AKT and ERK1/2 signaling pathways. Int J Oncol. 44:203–210. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Shen Y, Ichikawa H, Antes T and
Goldberg GS: Regulation of miRNA expression by Src and contact
normalization: Effects on nonanchored cell growth and migration.
Oncogene. 28:4272–4283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crawford M, Brawner E, Batte K, Yu L,
Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP:
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma
cell lines. Biochem Biophys Res Commun. 373:607–612. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito Y, Friedman JM, Chihara Y, Egger G,
Chuang JC and Liang G: Epigenetic therapy upregulates the tumor
suppressor microRNA-126 and its host gene EGFL7 in human cancer
cells. Biochem Biophys Res Commun. 379:726–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li XM, Wang AM, Zhang J and Yi H:
Down-regulation of miR-126 expression in colorectal cancer and its
clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Li N, Wu M, Li X, Luo Z and Wang X:
Expression of miR-126 suppresses migration and invasion of colon
cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan
WK, Tian T, Qiu YM and Luo HS: Down-regulation of miR-126 is
associated with colorectal cancer cells proliferation, migration
and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling
pathways. PLoS One. 8:e812032013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dumpati R, Ramatenki V, Vadija R, Vellanki
S and Vuruputuri U: Structural insights into suppressor of cytokine
signaling 1 protein-identification of new leads for type 2 diabetes
mellitus. J Mol Recognit. 31:e27062018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
White MF: The IRS-signalling system: A
network of docking proteins that mediate insulin action. Mol Cell
Biochem. 182:3–11. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang Q, Li Y, White MF, Fletcher JA and
Xiao S: Constitutive activation of insulin receptor substrate 1 is
a frequent event in human tumors: Therapeutic implications. Cancer
Res. 62:6035–6038. 2002.PubMed/NCBI
|
|
28
|
Esposito DL, Aru F, Lattanzio R, Morgano
A, Abbondanza M, Malekzadeh R, Bishehsari F, Valanzano R, Russo A,
Piantelli M, et al: The insulin receptor substrate 1 (IRS1) in
intestinal epithelial differentiation and in colorectal cancer.
PLoS One. 7:e361902012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Esposito DL, Verginelli F, Toracchio S,
Mammarella S, De Lellis L, Vanni C, Russo A, Mariani-Costantini R
and Cama A: Novel insulin receptor substrate 1 and 2 variants in
breast and colorectal cancer. Oncol Rep. 30:1553–1560. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li N, Li X, Huang S, Shen S and Wang X:
miR-126 inhibits colon cancer proliferation and invasion through
targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi
Xue Ban. 38:809–817. 2013.(In Chinese). PubMed/NCBI
|
|
31
|
Sorbin LH, Gospodarowicz MK and Wittekind
C: International Union against Cancer (UICC). TNM classification of
malignant tumors. 7. West Sussex; UK, Wiley-Blackwell: 2009
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurien BT and Scofield RH: Western
blotting: An introduction. Methods Mol Biol. 1312:17–30. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen WS, Chen TW, Yang TH, Hu LY, Pan HW,
Leung CM, Li SC, Ho MR, Shu CW, Liu PF, et al: Co-modulated
behavior and effects of differentially expressed miRNA in
colorectal cancer. BMC Genomics. 14 (Suppl 5):S122013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang YH, Jin M, Li J and Kong X:
Identifying circulating miRNA biomarkers for early diagnosis and
monitoring of lung cancer. Biochim Biophys Acta Mol Basis Dis.
1658472020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Noorolyai S, Baghbani E, Aghebati Maleki
L, Baghbanzadeh Kojabad A, Shanehbansdi D, Khaze Shahgoli V,
Mokhtarzadeh A and Baradaran B: Restoration of miR-193a-5p and
miR-146 a-5p expression induces G1 arrest in colorectal cancer
through targeting of MDM2/p53. Adv Pharm Bull. 10:130–134. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li XQ, Li L, Xiao CH and Feng YM: NEFL
mRNA expression level is a prognostic factor for early-stage breast
cancer patients. PLoS One. 7:e311462012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Salvatore L, Calegari MA, Loupakis F,
Fassan M, Di Stefano B, Bensi M, Bria E and Tortora G: PTEN in
colorectal cancer: Shedding light on its role as predictor and
target. Cancers (Basel). 11:17652019. View Article : Google Scholar
|
|
40
|
Li Z, Xue TQ, Yang C, Wang YL, Zhu XL and
Ni CF: EGFL7 promotes hepatocellular carcinoma cell proliferation
and inhibits cell apoptosis through increasing CKS2 expression by
activating Wnt/β-catenin signaling. J Cell Biochem.
119:10327–10337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tachibana H, Sho R, Takeda Y, Zhang X,
Yoshida Y, Narimatsu H, Otani K, Ishikawa S, Fukao A, Asao H and
Iino M: Circulating miR-223 in oral cancer: Its potential as a
novel diagnostic biomarker and therapeutic target. PLoS One.
11:e01596932016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Zhou Y, Fei X, Chen X and Zhu Z:
Regulator of G-protein signaling 3 targeted by miR-126 correlates
with poor prognosis in gastric cancer patients. Anticancer Drugs.
28:161–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang H, Mao F, Shen T, Luo Q, Ding Z,
Qian L and Huang J: Plasma miR-145, miR-20a, miR-21 and miR-223 as
novel biomarkers for screening early-stage non-small cell lung
cancer. Oncol Lett. 13:669–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ruan L and Qian X: MiR-16-5p inhibits
breast cancer by reducing AKT3 to restrain NF-κB pathway. Biosci
Rep. 39:BSR201916112019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi XY, Wang H, Wang W and Gu YH:
MiR-98-5p regulates proliferation and metastasis of MCF-7 breast
cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci.
23:2847–2855. 2019.PubMed/NCBI
|
|
47
|
Yang F, Yan Y, Yang Z, Hong X, Wang M,
Yang Y, Ye L and Liu B: miR-210 in exosomes derived from CAFs
promotes non-small cell lung cancer migration and invasion through
PTEN/PI3K/AKT pathway. Cell Signal. 73:1096752020.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lan F, Yue X and Xia T: Exosomal
microRNA-210 is a potentially non-invasive biomarker for the
diagnosis and prognosis of glioma. Oncol Lett. 19:1967–1974.
2020.PubMed/NCBI
|
|
49
|
Wang W, Qu A, Liu W, Liu Y, Zheng G, Du L,
Zhang X, Yang Y, Wang C and Chen X: Circulating miR-210 as a
diagnostic and prognostic biomarker for colorectal cancer. Eur J
Cancer Care. 22:Feb;2016.(Epub ahead of print).
|
|
50
|
Li M, Ma X, Li M, Zhang B, Huang J, Liu L
and Wei Y: Prognostic role of microRNA-210 in various carcinomas: A
systematic review and meta-analysis. Dis Markers. 2014:1061972014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nygren MK, Tekle C, Ingebrigtsen VA,
Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T,
Alsner J, et al: Identifying microRNAs regulating B7-H3 in breast
cancer: The clinical impact of microRNA-29c. Br J Cancer.
110:2072–2080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu W, He J, Chen D, Zhang B, Xu L, Ma H,
Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429
as potential biomarkers for detection of early stage non-small lung
cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu C, Cao Y, He Z, He J, Hu C, Duan H and
Jiang J: Serum levels of miR-19b and miR-146a as prognostic
biomarkers for non-small cell lung cancer. Tohoku J Exp Med.
232:85–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li Y, Sun J, Cai Y, Jiang Y, Wang X, Huang
X, Yin Y and Li H: MiR-200a acts as an oncogene in colorectal
carcinoma by targeting PTEN. Exp Mol Pathol. 101:308–313. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qian J, Jiang B, Li M, Chen J and Fang M:
Prognostic significance of microRNA-16 expression in human
colorectal cancer. World J Surg. 37:2944–2949. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao H, Xu Z, Qin H, Gao Z and Gao L:
miR-30b regulates migration and invasion of human colorectal cancer
via SIX1. Biochem J. 460:117–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pichler M, Ress AL, Winter E, Stiegelbauer
V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW,
Kiesslich T, et al: MiR-200a regulates epithelial to mesenchymal
transition-related gene expression and determines prognosis in
colorectal cancer patients. Br J Cancer. 110:1614–1621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu Y, Zhou Y, Feng X, Yang P, Yang J, An
P, Wang H, Ye S, Yu C, He Y and Luo H: Low expression of
microRNA-126 is associated with poor prognosis in colorectal
cancer. Genes Chromosomes Cancer. 53:358–365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dong Y, Fu C, Guan H, Zhang Z, Zhou T and
Li B: Prognostic significance of miR-126 in various cancers: A
meta-analysis. Onco Targets Ther. 9:2547–2555. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Qian Y and Wang X, Lv Z, Guo C, Yang Y,
Zhang J and Wang X: MicroRNA-126 is downregulated in thyroid cancer
cells, and regulates proliferation, migration and invasion by
targeting CXCR4. Mol Med Rep. 14:453–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ebrahimi F, Gopalan V, Wahab R, Lu CT,
Smith RA and Lam AK: Deregulation of miR-126 expression in
colorectal cancer pathogenesis and its clinical significance. Exp
Cell Res. 339:333–341. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wu L, Shi B, Huang K and Fan G:
MicroRNA-128 suppresses cell growth and metastasis in colorectal
carcinoma by targeting IRS1. Oncol Rep. 34:2797–2805. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yin Y, Yan ZP, Lu NN, Xu Q, He J, Qian X,
Yu J, Guan X, Jiang BH and Liu LZ: Downregulation of miR-145
associated with cancer progression and VEGF transcriptional
activation by targeting N-RAS and IRS1. Biochim Biophys Acta.
1829:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and
Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are
downstream targets of miR-126 in esophageal squamous cell
carcinoma. Oncol Rep. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Meyer K, Albaugh B, Schoenike B and Roopra
A: Type 1 insulin-like growth factor receptor/insulin receptor
substrate 1 signaling confers pathogenic activity on breast tumor
cells lacking REST. Mol Cell Biol. 35:2991–3004. 2015. View Article : Google Scholar : PubMed/NCBI
|
